We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




New Angioplasty System Alleviates Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 10 Feb 2021
Print article
Image: The Selution sustained limus release balloon (Photo courtesy of MedAlliance)
Image: The Selution sustained limus release balloon (Photo courtesy of MedAlliance)
A novel sirolimus-eluting balloon (SEB) treats long tibial occlusive lesions in peripheral artery disease (PAD) patients with critical limb ischemia (CLI).

The MedAlliance (Nyon, Switzerland) Selution sustained limus release (SLR) balloon technology is based on unique micro-reservoirs made from a biodegradable polymer intermixed with the anti-restenotic drug Sirolimus. The manufacturing process for the SEB micro-reservoirs results in millions of miniature, precisely formed, drug delivery pods, of uniform size and with the same drug elution properties. The micro-reservoirs bind to the surface of the SEB, using a proprietary cell adherent technology (CAT) process.

This mixes the micro-reservoirs with amphiphatic lipids--containing both positive and negative ions--that envelop them to ensure they remain on the SBE during its insertion into the artery and delivery to the lesion. Once expanded, the amphiphatic lipid carrier is attracted to negatively charged membranes in the endothelial cells, resulting in adhesion of the micro- reservoir coating, and subsequently providing the controlled, sustained release of the drug. After more than 90 days, the micro-reservoirs are fully biodegraded, and the vessel is returned to its natural state, with nothing left behind.

“Selution SLR is designed to deliver the same safety and performance as best-in-class drug eluting stent technology, with the added benefit of leaving nothing behind,” said Jeffrey Jump, chairman and CEO of MedAlliance. “Our breakthrough technology has shown to be effective and safe in below the knee diseases in highly complex patients.”

Sirolimus is a macrolide rapamycin (mTOR) macrocyclic lactone inhibitor used to coat coronary stents, prevent organ transplant rejection, and treat a rare lung disease called lymphangioleiomyomatosis. It is naturally produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972 by Surendra Nath Sehgal from samples found on Easter Island, which led to its original name, rapamycin after the native name of the island, Rapa Nui.

Related Links:
MedAlliance

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Steam Sterilizer
2000 RBE

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.